NasdaqCM:MLTXBiotechs
How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors
MoonLake Immunotherapeutics recently reported long-term Week 40 Phase 3 VELA-1 and VELA-2 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing strong efficacy on HiSCR75 and quality-of-life endpoints with a stable safety profile.
An interesting feature of these results is the use of a higher HiSCR75 threshold as the primary endpoint, positioning sonelokimab against existing IL-17A and IL-17A/F therapies on a more stringent efficacy measure.
We’ll now examine how...